 |
Business Wire - November 14, 2003
-- Presentation to Focus on Positive Phase II Results for HIV Immuno-Modulator with Antiviral Properties
-- One-on-One Meetings Scheduled with Over Twenty Pharmaceutical Companies
Samaritan Pharmaceuticals Inc. and Samaritan Research Labs, Georgetown University, announced today, it has been selected to present at Bio-Europe 2003's "Building Value Through Partnerships" partnering conference, at the Hotel Maritim, Frankfurt, Germany, at 12:45 PM November 19, 2003.
Additionally, Samaritan has a full schedule of one-on-one partnering meeting, with business development executives, to initiate partnerships throughout the Bio-Europe conference, Nov. 17-19, 2003.
Bio-Europe is an international partnering conference with over 1100 attendees, where biotechnology, pharmaceutical, and financial executives meet to initiate or develop partnerships between their companies. Dr. Janet Greeson, CEO and Chairman of Samaritan stated, "We are very excited to present in the infectious disease section and by the overwhelming expression of interest in our pipeline."
About Samaritan Pharma: "A Little Bridge Can Go a Long Way"
Samaritan Pharmaceuticals bridges scientific innovation to commercialization. Presently, Samaritan is striving to advance its HIV FDA-Phase II Immuno-modulator drug with antiviral properties, through regulatory affairs. Additionally, in collaboration with Georgetown University, Samaritan has developed a unique pipeline of AIDS, Alzheimer's and Cancer drug candidates, and diagnostics, for future commercialization.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed May 15, 2003. The company undertakes no duty to update forward-looking statements.
Contact: Samaritan Pharmaceuticals, Inc., 702/735-7001, Fax 702/737-7016
Gene Boyle, Business Development, Email GeneBoyle@aol.com
Doug Bessert, Investor Relations, Email DougBessert@aol.com
To receive future press releases and newsletters automatically, or for more information, visit our Web site at www.samaritanpharmaceuticals.com.
CONTACT: Samaritan Pharmaceuticals
Gene Boyle, 702-735-7001, or 702-499-8652
Fax 702-737-7016
GeneBoyle@aol.com
SOURCE: Samaritan Pharmaceuticals, Inc.
031114
BW031108
Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .